tech2 News Staff

Bharat Biotech underplays adverse event in Covaxin Phase 1 trial

The volunteer, who had no comorbidities, developed viral pneumonitis after being given a dose of the COVAXIN shot. An illustration of COVAXIN, the vaccine candidate for COVID-19 developed by Bharath Biotech. Image: Bharath Biotech Bharat Biotech, during its phase 1 trials, experienced an adverse event in a volunteer that it did not promptly admit to the public. […]Read More

WHO urges against remdesivir for COVID-19 as health experts clash

The drug is given intravenously, costly and complex to administer, the panel concluded that it has no meaningful effect on death rates or other important outcomes for patients. A bottle containing the drug Remdesivir is held by a health worker at the Institute of Infectology of Kenezy Gyula Teaching Hospital of the University of Debrecen […]Read More

Six months after first Ebola case recorded, outbreak in Congo

tech2 News StaffNov 20, 2020 18:09:31 IST The Democratic Republic of Congo (DRC) recently declared the end of the country’s latest Ebola epidemic in the Equateur province in the north-west of the country. The announcement comes almost six months since the first case was detected on 1 June 2020, and the province has recorded no new cases for over 48 […]Read More

Biological E starts Phase I/II trial, Bharat Bio to begin

Both the vaccines candidates will be administered in two doses via intramuscular injections 28 days apart. Biological E. Ltd will start Phase I and II human trials while Bharat Biotech will begin Phase III. Hyderabad-based Biological E Ltd has begun an adaptive Phase I and II human trial for its COVID-19 vaccine candidate. The firm has already sought […]Read More

Feluda paper strip test for COVID-19 to be available in

The CRISPR Feluda COVID-19 test was given approved for use by the Indian Council of Medical Research in September. A positive CRISPR Feluda paper strip test. PTI The Feluda paper strip test to diagnose COVID-19 , which is being touted as a “cheaper, faster alternative to RT-PCR” has entered Delhi markets today, and will be available in […]Read More

Seven in ten younger COVID-19 patients show 'mild' organ damage

The findings suggest that COVID-19 patients, even those with mild-to-moderate symptoms, need proper healthcare to overcome the infection completely. This study looked at the effects of long COVID in the younger population. We’ve heard many anecdotes of elder people bearing the brunt of the harshest COVID-19 symptoms during the start of the pandemic. The younger […]Read More

Sputnik V vaccine: Russia says initial results from Phase 3

The Sputnik V vaccine, developed by the Gamaleya Scientific Research Institute and the Russian defence ministry, is a two-shot vaccine. Russian’s Sputnik V COVID-19 vaccine is also under WHO’s pre-approval process. Image: RDIF After a vaccine developed by Pfizer and BioNTech recently showed that it was over 90 percent effective in preventing the infection, Russia […]Read More

Pfizer, BioNTech announce COVID-19 mRNA-based vaccine candidate, interim results show

A key safety milestone for the vaccine candidate is expected to occur in the second half of November. Illustration of vials of COVID-19 vaccine. Image: Igor Golovniov/SOPA Images An mRNA-based vaccine candidate against the SARS-CoV-2 being developed by Pfizer and BioNTech has shown promising results in people that weren’t previously infected by the virus. The findings from […]Read More